CGT
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SUSTAINABILITY
MORE
EXPERT VIEWS
INTERVIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK 2026
Subscribe
CGT
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SUSTAINABILITY
MORE
EXPERT VIEWS
INTERVIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK 2026
SEARCH
SEARCH
advanced search
Editor's pick
Popular
EXPERT VIEW
TRENDS FOR 2026
INTERVIEW
Interview: DARE IDDS – A Long-Term Subcutaneously Implanted Drug Delivery Device
EXPERT VIEW
FRACTIONAL INVESTMENT IN DEVICE PLATFORMS – A NEW FUNDING PARADIGM
THE POWER OF PARTNERSHIP AND CLOSE COLLABORATION FOR FILLING ON-BODY INJECTORS
(5518 views)
ADVANCING SUBCUTANEOUS INFUSION THERAPY FOR PATIENTS THROUGH INNOVATION AND PARTNERSHIPS
(5041 views)
GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES
(3913 views)
INTERVIEW
Interview: Enhancing Clinical Trials with CliniPilot
®
and Clear to Clinic™ Programme
Dr Carolina Canapè and Roger Lüscher talk with Guy Furness about the application of connectivity in decentralised trials, and how Ypsomed’s CliniPilot and the company’s range of clinic-ready autoinjectors support faster, more efficient and more effective clinical trials.
INTERVIEW
Interview: Developing Wearable Injectors
Liat Shochat discusses her extensive experience in wearable drug delivery device development, covering the various challenges that arise from the inherent complexity of these devices, even with multiple successful wearable devices on the market, as well as the best way to engage with contract development organisations such as EdgeOne Medical.
VIDEO
John Merhige
Dual-Chamber Syringes, New Partnerships, and Speed-to-Market Pressures Shape 2026
John Merhige outlines his key themes shaping drug delivery in 2026: new momentum from a dual-chamber syringe fill-finish collaboration, a newly announced commercial supply agreement with a major global pharma company, and growing pressure to deliver increasingly complex molecules faster and more efficiently.
EXPERT VIEW
Tom Oakley
TRENDS FOR 2026
A new reality is forming as we enter 2026 – it will not be “business as usual”. Geopolitical forces in the largest market for pharmaceuticals, the US, are likely to mean substantial changes. Here, Tom Oakley and Alex Vasiev cover those changes, the incretin juggernaut and the march of technical progress with “minitablet” dispensers, large-volume injectors and dual-chamber devices.
INDUSTRIALISATION
Justin Schroeder
ACCELERATING PATIENT-CENTRIC THERAPIES FROM DEVELOPMENT TO DELIVERY
Justin Schroeder outlines its product service offering to the drug delivery industry, including sterile fill-finish services, drug-device combination product development and testing, clinical and commercial device assembly, packaging, storage and distribution, among other services.
PREFILLED SYRINGES
David Pircher
TIME TO MARKET: INCREASED CUSTOMER VALUE THROUGH GLOBAL RAMP-UP EXCELLENCE
David Pircher and Leander Moser discuss the advantages of having a global presence, which combines both local expertise and technical excellence with worldwide co-ordination of supply to deliver consistent and quality solutions.
PREFILLED SYRINGES
Asmita Khanolkar
EARLY AUTOMATION CONSIDERATIONS FOR THE DEVELOPMENT OF DRUG DELIVERY COMBINATION PRODUCTS
Asmita Khanolkar and Al Neumann, uncover the manufacturing strategies that can be used to achieve design for automation, scale-up and sustainable solutions for clinical and commercial launch, describing the gains to be made in manufacturing efficiency when using small, automated work cells.
CONNECTIVITY
Giacomo Bruno
FRICTIONLESS ENGAGEMENT: HOW GX INMONIT™ CAN SIMPLIFY SELF-INJECTION AND STRENGTHENS PATIENT ADHERENCE
Dr Giacomo Bruno and Simon Buerdel consider the causes of patient non-adherence and its subsequent effects on healthcare systems, going on to present the solutions created by Gerresheimer to address the patient experience across treatment types.
PREFILLED SYRINGES
Wolfgang Moersch
TESTING AUTOINJECTORS ACCORDING TO ISO 11608-5 TO INCREASE RELIABILITY AND BOOST EFFICIENCY
Wolfgang Moersch discusses the role of automation in testing injection devices – including autoinjectors, pen injectors and on-body injectors – and how advanced testing software and robotics solutions can provide more accurate and consistent testing results.
PREFILLED SYRINGES
Stefan Schreiber
SAFETY BY DESIGN FOR DRUG DELIVERY DEVICES
Professor Stefan Schreiber, Dr Theo Wember and Sebastian Block discuss how using Design of Experiments methodology can provide insights into the manufacturing process of power springs that can enable manufacturers to more robustly control variables and produce more consistent outputs.
PREFILLED SYRINGES
Matthias Müller
FROM CONCEPT TO SERIES PRODUCTION – ACCELERATING INDUSTRIALISATION IN MEDTECH
Matthias Müller and Sven Müller discuss Contexo and Probotec's combined approach to scaling drug-device combination products from laboratory prototypes to fully validated GMP commercial-scale production lines.
INTERVIEW
Aurelie Rebuffet
Interview: New But Not News – A Smooth Transition to USP <382> with Established Expertise
Dr Aurélie Rebuffet and Virginie Jeymond, discuss the new requirements set out in the US Pharmacopeia (USP) Chapter <382>, including the shift towards assessing the drug-device combination product as a holistic whole and how ZebraSci and BD can support pharma companies in complying with USP <382>.
INJECTION
Landon Goldfarb
BUILDING STRATEGIC PARTNERSHIPS FOR EARLY-STAGE DRUG DELIVERY DEVICE TESTING
Landon Goldfarb considers the importance of relationships between formulation and delivery teams for pharmaceutical innovation, highlighting a framework to differentiate between an equipment supplier and a testing partner, outlining the system capabilities and organisational competencies required to create effective early device-development teams.
CONFERENCE SHOWCASE
Sherma Ellis Daal
REDEFINING THE ROLE OF PACKAGING IN A DEMANDING PHARMACEUTICAL LANDSCAPE
Ahead of this year’s Pharmapack Europe conference on Jan 21–22, 2026, Sherma Ellis Daal discusses the role of packaging and drug delivery systems in the wider pharmaceutical industry, offering insights on how key trends and pressures are changing thinking and redefining what makes a successful project.
EXPERT VIEW
Oliver Eden
DEVELOPMENTAL ADVANTAGES IN INJECTABLE COMBINATION DRUG PRODUCTS
Oliver Eden and Travis Webb consider how regulatory considerations and patient-centric device designs are transforming the landscape of self-administered injectable drugs.
INTERVIEW
Liz Proos
Interview: DARE IDDS – A Long-Term Subcutaneously Implanted Drug Delivery Device
Liz Proos and Ashley Hawson talk exclusively with ONdrugDelivery's Guy Furness about the DARE Intelligent Drug Delivery System – an advanced, connected implantable device that delivers programmable doses for up to a decade – its place in the market, the challenges faced during its design and its potential as novel drug delivery device.
EXPERT VIEW
Angela Shotton
DESIGNING SUSTAINABLE DRUG DELIVERY DEVICE PACKAGING: TRENDS, CHALLENGES AND REGULATORY IMPLICATIONS
Angela Shotton and Nic Hunt, look at the evolving landscape of the pharmaceutical packaging landscape and consider how the industry is meeting sustainability and regulatory requirements.
EXPERT VIEW
Paul Jansen
FRACTIONAL INVESTMENT IN DEVICE PLATFORMS – A NEW FUNDING PARADIGM
Drawing on his extensive experience in the drug delivery device industry, Paul Jansen considers how funding for delivery device development has shifted over the years, from the pre-platform model to currently accepted practice and looks forward to how it may further evolve to support the development of novel devices in the biologics space and beyond.
EXPERT VIEW
Tim Quigg
THE PLATFORM PARADOX: DEVICE DEVELOPMENT CHALLENGES WITHIN FAST EVOLVING DRUG DISCOVERY PIPELINES
Tim Quigg, Mariam Al-Amari and Joel Gresham discuss how to enable high-dose delivery for novel biologics, using
ex vivo
and
in silico
approaches to accelerate drug-device development and improve device performance, thus de-risking projects and saving costs.
FORMULATION
Liliana Miinea
FROM BRICK-DUST DRUGS TO BREAKTHROUGHS: TRANSFORMING DRUG DELIVERY WITH NOVEL EXCIPIENTS
Dr Liliana Miinea of Lubrizol discusses how next-generation excipients can help formulators realise the potential of promising but poorly soluble drug candidates, including Lubrizol’s Apisolex™ and Apinovex™ polymer excipients for parenteral and oral applications.
PREFILLED SYRINGES
Hiroki Hasegawa
USING OXYCAPT™ MULTILAYER PLASTIC VIAL FOR GENE AND CELL THERAPIES STORED IN DRY ICE AND LIQUID NITROGEN
Hiroki Hasegawa and Tomohiro Suzuki consider the various challenges presented by cold-chain logistics to both traditional glass vials and many cyclo-olefin polymer alternatives, and how Mitsubishi Gas Chemical's OXYCAPT™ vials offer significant advantages for maintaining container closure integrity compared with other materials on the market.
CGT
Krishnendu khan
PRIMARY PACKAGING AND ADMINISTRATION OF CELL THERAPIES: CURRENT TRENDS AND CHALLENGES
Dr Krishnendu Khan and Henry Nguyen of West Pharmaceutical Services examine factors to consider when designing and selecting primary packaging for cell therapies, exploring the effects of cryogenic storage on packaging and cells, while highlighting the diverse delivery methods and applications for these therapies.
EXPERT VIEW
Fiona McLaughlin
IMPROVING RNA THERAPEUTIC TARGETING BEYOND DELIVERY
Dr Fiona McLaughlin and Dr Mark Edbrooke discuss the possibilities for developing novel cancer treatments using functionalised nanoparticles, in order to transport a variety of therapies into the tumour microenvironment.
EXPERT VIEW
Max Chambers
REVEALING THE FRONTIER: DRUG DELIVERY CHALLENGES AND INNOVATIONS IN OCULAR GENE THERAPY
Dr Max Chambers discusses novel approaches for delivering ocular gene therapies, summarising the challenges and benefits of various delivery routes and exploring the devices used to successfully improve vision.
EARLY INSIGHT
Steven Gill
PRECISION DELIVERY: SEAMLESS COLLABORATION FOR DELIVERING NEURO-THERAPEUTICS
Professor Steven Gill and Alan Suttie provide insight into the unique collaboration and design philosophy behind their novel scalable interventional delivery system for gene and cell therapies – the Neurochase Acute Drug Delivery System.
EXPERT VIEW
Bharat Arora
DRUG DELIVERY IN CELL AND GENE THERAPY: WHY EARLY DEVICE DEVELOPMENT MATTERS
Bharat Arora discusses how the delivery method for a cell and gene therapy is an integral part of the overall product, inextricable from the therapy itself, and how properly synchronising drug and delivery device development can greatly benefit the overall development programme.
1
2
3
…
69
Next
Top
